Related Experiment Video

Updated: May 15, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Targeting HER2-positive cancer cells with receptor-redirected anthrax protective antigen

Andrew J McCluskey1, Andrew J Olive, Michael N Starnbach

  • 1Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA.

Molecular Oncology
|January 8, 2013
PubMed

Insights

Researchers engineered anthrax toxin to target HER2-positive cancer cells. This novel targeted toxin effectively killed cancer cells, including resistant types, without harming healthy cells, offering a promising new cancer therapy approach.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Targeted therapeutics are crucial for cancer treatment.
  • Modifying protein toxins offers a strategy for selective cancer cell ablation.
  • HER2 is a key marker in breast and ovarian cancers.

Purpose of the Study:

  • To engineer a targeted toxin for HER2-positive tumors.
  • To evaluate the efficacy and specificity of the modified toxin.
  • To assess the potential of anthrax toxin as a cancer therapeutic platform.

Main Methods:

  • Receptor-binding domain of anthrax toxin (Protective Antigen, PA) was modified.
  • Fusion protein (mPA-ZHER2) was created to target HER2 receptors.
  • Cytotoxicity assays were performed on HER2-positive and HER2-negative cells.

Main Results:

  • The mPA-ZHER2 fusion protein specifically killed HER2-positive cancer cells, including trastuzumab-resistant lines.
  • No significant killing of HER2-negative cells was observed.
  • Combinations of toxins targeting different receptors showed selective cell killing.

Conclusions:

  • Engineered anthrax toxin effectively targets and eliminates HER2-positive cancer cells.
  • This approach demonstrates specificity and avoids off-target effects.
  • Anthrax toxin is a viable platform for developing targeted cancer therapeutics.

More Related Videos

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Receptor-mediated Endocytosis01:20

Receptor-mediated Endocytosis

Receptor-mediated endocytosis is when bulk amounts of specific molecules are imported into a cell after binding to cell surface receptors. The molecules bound to these receptors are taken into the cell through inward folding of the cell surface membrane, which is eventually pinched off into a vesicle within the cell. Structural proteins, such as clathrin, coat the budding vesicle.
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...